Center for Disease Neurogenomics

The Center for Disease Neurogenomics (CDN) is expanding our knowledge of the genetic, cellular, and molecular processes that contribute to neuropsychiatric diseases. The overarching goal of the Center is to promote precision psychiatry by identifying the genetic variants and underlying mechanisms that cause disease and, ultimately, enabling personalized therapy.

We are pioneering new techniques, systems, and processes to advance our goals. The Center studies Alzheimer’s disease, schizophrenia, Parkinson’s disease, bipolar disorder, and other neuropsychiatric and neurodegenerative diseases. These diseases exact an enormous toll—both in terms of quality of life and health care costs—on a broad spectrum of the population.

The Center is one of the few institutions in the world to have access to brain tissue and important datasets that reflect population-level sample sizes. The Center utilizes electronic health records, such as the Million Veteran Program and Mount Sinai’s BioMe. Our group is leading efforts within brain omics consortia such as PsychENCODE, the CommonMind Consortium, NIH's Brain Research Through Advancing Innovative Neurotechnologies (BRAIN), and multiple programs supported by the Accelerating Medicines Partnership (AMP) that focus on Alzheimer’s disease (AMP-AD), Parkinson’s disease (AMP-PD) and cardiometabolic disease (AMP-CMD).